The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report

Joyce Cui; Sana Tabbara; Juskaran Chadha

doi:10.1177/2050313X231196663

The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report

SAGE Open Med Case Rep. 2023 Aug 30:11:2050313X231196663. doi: 10.1177/2050313X231196663. eCollection 2023.

Authors

Joyce Cui¹, Sana Tabbara², Juskaran Chadha²

Affiliations

¹ University of South Florida Morsani School of Medicine, Tampa, FL, USA.
² Moffitt Cancer Center, Tampa, FL, USA.

Abstract

EGFR mutations comprise a sizeable portion of non-small cell lung cancers. While the most common EGFR mutation consists of exon 19 in-frame deletions and exon 21 point mutations, rare EGFR mutations have become a more frequent occurrence. Currently, no clinical guidelines exist for the treatment of such mutations. In this case, we see a 68-year-old non-small cell lung cancer male patient with a history of smoking presenting with a rare exon 20 R776H EGFR mutation who demonstrates a response to Osimertinib, further exploring potential standard treatments for patients with rare EGFR mutations.

Keywords: EGFR TKI; NSCLC; Oncology; exon 20.

Publication types

Case Reports